OSE Immunotherapeutics Stock OTC Markets
Stocks
ORPHF
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 61.86M 70.94M 58.41M 53.04M 99.37M 6.81B 99.79M 700M 270M 3.46B 266M 261M 11.14B | P/E 2026 * |
-2.02x | P/E 2027 * | -2.32x |
|---|---|---|---|---|---|
| Enterprise Value | 103M 118M 96.92M 88.01M 165M 11.3B 166M 1.16B 448M 5.74B 442M 432M 18.48B | EV / Sales 2026 * |
20.9x | EV / Sales 2027 * | 11.9x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: OSE Immunotherapeutics
| 1 day | +190.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 02/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 20/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 20/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 31/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 14/06/2017 |
| Director/Board Member | - | 22/06/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +190.00% | +143.99% | - | - | 70.94M | |
| +0.11% | +2.71% | +0.44% | +26.85% | 46.28B | |
| -1.12% | +1.78% | +42.30% | +27.55% | 43.85B | |
| -3.04% | -6.29% | +338.56% | +515.97% | 40.93B | |
| -0.74% | +1.25% | +4.92% | +67.98% | 39.89B | |
| -0.50% | +0.67% | +10.29% | +41.28% | 29.5B | |
| -0.46% | +4.22% | +22.81% | +139.44% | 17.09B | |
| -0.97% | -10.17% | - | - | 15.55B | |
| -0.57% | +8.12% | +22.19% | +38.68% | 15.22B | |
| -3.14% | +31.91% | -11.79% | - | 14.05B | |
| Average | +17.96% | +3.76% | +53.72% | +122.54% | 29.15B | |
| Weighted average by Cap. | -1.05% | +1.87% | +68.04% | +130.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.62M 4.63M 4.2M 7.87M 539M 7.9M 55.42M 21.39M 274M 21.11M 20.64M 882M | 10.53M 12.08M 9.94M 9.03M 16.92M 1.16B 16.99M 119M 45.96M 589M 45.36M 44.36M 1.9B |
| Net income | -30.59M -35.08M -28.88M -26.23M -49.14M -3.37B -49.34M -346M -133M -1.71B -132M -129M -5.51B | -21.47M -24.62M -20.27M -18.41M -34.49M -2.36B -34.63M -243M -93.7M -1.2B -92.48M -90.42M -3.86B |
| Net Debt | 40.79M 46.78M 38.52M 34.98M 65.53M 4.49B 65.8M 461M 178M 2.28B 176M 172M 7.34B | 63.08M 72.34M 59.57M 54.09M 101M 6.94B 102M 714M 275M 3.53B 272M 266M 11.36B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
